August 7, 2019
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer(Securities Code: 4582)

Revision to Earnings Forecasts for FY 2019and Mid-Range Plan (FY 2019 to FY 2022)
TOKYO, Japan, August 7, 2019 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio")
today announced that the Company’s Board of Directors today approved the following revision to theEarnings Forecasts for the fiscal year ending December 31, 2019 and the Mid-Range Plan for the fiscalyears ending December 31, 2019 to 2022, previously announced on February 7, 2019, in accordancewith the current performance trend and outlook.
1. Revision to Earnings Forecast(1) Revision to the earnings forecast for FY 2019 (January 1, 2019 to December 31, 2019)
Earnings
Operating
OrdinaryNet(Loss)
Net Sales
Profit (Loss)
Profit (Loss)
Profit (Loss)
per Share
Million of Yen

Million of Yen

Million of Yen

Million of Yen

Yen

Previous Forecast (A)4,465

ᇞ3,587

ᇞ3,612

ᇞ3,616

ᇞ175.52

Revised Forecast (B)3,092

ᇞ3,780

ᇞ3,856

ᇞ3,859

ᇞ167.66

Change Amount (B-A)

ᇞ1,372

ᇞ193

ᇞ244

ᇞ243

Change Percentage (%)ᇞ30.7－－－－

3,835

ᇞ2,656

ᇞ2,748

ᇞ2,752

ᇞ165.52－[Reference] Prior YearResults (FY 2018)(2) Reason for Revision
The Company currently imports lyophilized powder formulation of TREAKISYM® from Astellas
Deutschland GmbH (“Astellas Germany”), a consolidated subsidiary of Astellas Pharma Inc. (“AstellasPharma”) and, after carrying out quality testing and packaging, markets the product in Japan throughits business partner, Eisai. During the second quarter of the fiscal year ending December 31, 2019, theinclusion of foreign substance or visual defects were detected in the 100mg presentation ofTREAKISYM® imported from Astellas Germany at a rate significantly higher than what is permissible
under the quality standards agreed between the Company and Astellas Germany. The Company will
return all defective batches to Astellas Germany and has asked Astellas to ensure that all future1

shipments are free from such quality issues. At the same time, the Company has urged Astellas
Germany to identify the root causes of defects and accelerate the manufacturing and supply ofreplacement batches.
Under these circumstances, shipments in the second half of 2019 may be below the Company’s originallyplanned shipment volume as supply of replacement batches may be delayed to the first quarter of 2020.
Accordingly, the Company has determined to revise the Earnings Forecast for the fiscal year ending
December 2019.
The increase in Operating Loss shown above is the result of a reduction in Net Sales, partially mitigatedby a 294 million yen reduction in Selling, General and Administrative Expenses (reduced to 4,760
million yen from the originally anticipated 5,053 million yen).
The Company has urged Astellas Germany as the supplier, and Astellas Pharma, to ensure that productsupply obligations are met. The Company will advance the discussion to fulfill its responsibility toensure stable supply of high-quality product, which is an essential part of its mission as apharmaceutical company.
2. Revision to the Mid-Range Plan
(1) Revision to the planned figures

Previous Plan

Revised Plan

for FY 2019

for FY 2019

Million of Yen

Million of Yen

4,465

3,093

Operating Profit (Loss)

ᇞ3,587

ᇞ3,780Ordinary Profit (Loss)

ᇞ3,612

ᇞ3,857

Net Profit (Loss)

ᇞ3,616

ᇞ3,859Net Sales(2) Reason for Revision
The reason for the revision to the earnings forecast for FY 2019 is stated in 1- (1) above.
The Company is currently assessing the potential impact on fiscal years 2020, 2021 and 2022 in theMid-Range Plan. Any material impact will be disclosed by the Company in a timely manner.
*Earnings forecasts, financial projections, and other forecasts or forward looking statements containedin this disclosure have been prepared by the Company at its discretion and based on information
available to the Company as of the date of this disclosure. Actual results may differ materially from theinformation contained in this disclosure as a result of changes to assumptions or conditions.
[Contact]
Investor Relations
Tel: +81 (0)3 5472 11252